Skip to main
ACHV

ACHV Stock Forecast & Price Target

ACHV Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Achieve Life Sciences Inc. is positioned favorably within the pharmaceutical market due to its commitment to advancing cytisinicline, an established treatment for nicotine addiction that has demonstrated significant efficacy and a favorable safety profile. The company reported impressive market data, with smoking cessation rates showing a dose-dependent improvement, suggesting strong potential for achieving higher sales, which reached $1.6 billion. Furthermore, the planned expansion into the vaping segment and the availability of flexible dosing schedules enhance the product's appeal, potentially driving long-term appreciation in shareholder value.

Bears say

Achieve Life Sciences faces a negative outlook primarily due to concerns regarding the commercial viability of cytisinicline, despite its statistical efficacy in reducing nicotine addiction symptoms. Analyst projections illustrate a bear case scenario where, although cytisinicline may gain approval for cigarette smoking cessation, it is expected to underperform in sales due to slower than anticipated market adoption and decreased penetration in the vaping segment. Furthermore, the observed clinical challenges, such as reliance on alternative therapies like bupropion among depressed patients, may further hinder cytisinicline's market success and overall revenue potential.

ACHV has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achieve Life Sciences (ACHV) Forecast

Analysts have given ACHV a Buy based on their latest research and market trends.

According to 2 analysts, ACHV has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achieve Life Sciences (ACHV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.